Clinical meaning
Suicidal behavior results from complex interactions between neurobiological vulnerability, psychological distress, and environmental stressors. The serotonergic system plays a central role: post-mortem studies of suicide victims consistently show reduced serotonin transporter (SERT) binding and decreased serotonin metabolite (5-HIAA) levels in the prefrontal cortex and brainstem raphe nuclei. This serotonergic deficit impairs inhibitory control over impulsive aggressive behavior mediated by the ventral prefrontal cortex. The hypothalamic-pituitary-adrenal (HPA) axis shows hyperactivity with elevated cortisol levels, reflecting chronic stress dysregulation. Neuroinflammation with elevated IL-6, TNF-alpha, and C-reactive protein is increasingly recognized as contributing to suicidal ideation through effects on tryptophan metabolism (kynurenine pathway) that further deplete serotonin. Genetic factors account for approximately 40% of suicidal behavior variance, with polymorphisms in genes encoding the serotonin transporter (SLC6A4), BDNF, and HPA axis components conferring vulnerability. The means restriction approach to prevention is based on evidence that reducing access to lethal means (firearms, medications, ligature points) during acute crisis significantly reduces suicide mortality because most suicidal crises are time-limited, and survivors of attempts rarely go on to die by suicide.